179 related articles for article (PubMed ID: 37858847)
1. Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity: A Three Dimentional Echocardiography Study.
Mohamed AL; El-Abd AA; Mohamed HG; Noufal AM; Hennawy BS
Curr Probl Cardiol; 2024 Jan; 49(1 Pt C):102130. PubMed ID: 37858847
[TBL] [Abstract][Full Text] [Related]
2. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.
Thavendiranathan P; Houbois C; Marwick TH; Kei T; Saha S; Runeckles K; Huang F; Shalmon T; Thorpe KE; Pezo RC; Prica A; Maze D; Abdel-Qadir H; Connelly KA; Chan J; Billia F; Power C; Hanneman K; Wintersperger BJ; Brezden-Masley C; Amir E
Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):515-525. PubMed ID: 37120736
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Neilan TG; Quinaglia T; Onoue T; Mahmood SS; Drobni ZD; Gilman HK; Smith A; Heemelaar JC; Brahmbhatt P; Ho JS; Sama S; Svoboda J; Neuberg DS; Abramson JS; Hochberg EP; Barnes JA; Armand P; Jacobsen ED; Jacobson CA; Kim AI; Soumerai JD; Han Y; Friedman RS; Lacasce AS; Ky B; Landsburg D; Nasta S; Kwong RY; Jerosch-Herold M; Redd RA; Hua L; Januzzi JL; Asnani A; Mousavi N; Scherrer-Crosbie M
JAMA; 2023 Aug; 330(6):528-536. PubMed ID: 37552303
[TBL] [Abstract][Full Text] [Related]
5. Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial.
Čiburienė E; Aidietienė S; Ščerbickaitė G; Sadauskienė E; Sudavičienė D; Baltruškevičienė E; Brasiūnienė B; Drobnienė M; Čelutkienė J
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138243
[No Abstract] [Full Text] [Related]
6. Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer.
Yu AF; Moore ZR; Moskowitz CS; Liu JE; Dang CT; Ramanathan L; Oeffinger KC; Steingart RM; Schmitt AM
JAMA Cardiol; 2023 Jul; 8(7):697-702. PubMed ID: 37256614
[TBL] [Abstract][Full Text] [Related]
7. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional speckle-tracking echocardiography for the global and regional assessments of left ventricle myocardial deformation in breast cancer patients treated with anthracyclines.
Coutinho Cruz M; Moura Branco L; Portugal G; Galrinho A; Timóteo AT; Rio P; Ilhão Moreira R; Mendonça T; Leal A; Gameiro F; Duarte Oliveira S; Luz R; Cruz Ferreira R
Clin Res Cardiol; 2020 Jun; 109(6):673-684. PubMed ID: 31559482
[TBL] [Abstract][Full Text] [Related]
9. Two-dimensional speckle tracking echocardiography help identify breast cancer therapeutics-related cardiac dysfunction.
Liu W; Li W; Li H; Li Z; Zhao P; Guo Z; Liu C; Sun L; Wang Z
BMC Cardiovasc Disord; 2022 Dec; 22(1):548. PubMed ID: 36522712
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
[TBL] [Abstract][Full Text] [Related]
11. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and Prognostic Value of Myocardial Work Indices for Identification of Cancer Therapy-Related Cardiotoxicity.
Calvillo-Argüelles O; Thampinathan B; Somerset E; Shalmon T; Amir E; Steve Fan CP; Moon S; Abdel-Qadir H; Thevakumaran Y; Day J; Woo A; Wintersperger BJ; Marwick TH; Thavendiranathan P
JACC Cardiovasc Imaging; 2022 Aug; 15(8):1361-1376. PubMed ID: 35926895
[TBL] [Abstract][Full Text] [Related]
13. Superiority of left heart deformation in early anthracycline-related cardiac dysfunction detection.
Giang M N; Nguyen H H; Vo DT; Ho Huynh Quang T; Phan DTH; Chau NH
Open Heart; 2023 Nov; 10(2):. PubMed ID: 38011990
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of Panax ginseng against doxorubicin-induced cardiac toxicity in patients with non-metastatic breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
Hamidian M; Foroughinia F; Haghighat S; Attar A; Haem E
J Oncol Pharm Pract; 2023 Sep; 29(6):1306-1316. PubMed ID: 35975564
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients from Southern Sri Lanka: An Echocardiographic Analysis.
Sandamali JAN; Hewawasam RP; Fernando MACSS; Jayatilaka KAPW; Madurawe RD; Sathananthan PP; Ekanayake U; Horadugoda J
Biomed Res Int; 2020; 2020():1847159. PubMed ID: 33274195
[TBL] [Abstract][Full Text] [Related]
16. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
[TBL] [Abstract][Full Text] [Related]
17. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients.
Howden EJ; Bigaran A; Beaudry R; Fraser S; Selig S; Foulkes S; Antill Y; Nightingale S; Loi S; Haykowsky MJ; La Gerche A
Eur J Prev Cardiol; 2019 Feb; 26(3):305-315. PubMed ID: 30376366
[TBL] [Abstract][Full Text] [Related]
18. Relationship between regional left ventricular dysfunction and cancer-therapy-related cardiac dysfunction.
Saijo Y; Kusunose K; Okushi Y; Yamada H; Toba H; Sata M
Heart; 2020 Nov; 106(22):1752-1758. PubMed ID: 32209616
[TBL] [Abstract][Full Text] [Related]
19. Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity.
Lambert J; Lamacie M; Thampinathan B; Altaha MA; Esmaeilzadeh M; Nolan M; Fresno CU; Somerset E; Amir E; Marwick TH; Wintersperger BJ; Thavendiranathan P
Heart; 2020 Jun; 106(11):817-823. PubMed ID: 32098808
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]